Health Systems and Life Sciences Companies—Changing COVID-19 Care Using Data
Clinicians, scientists, and researchers are learning more about SARS-CoV-2 (COVID-19) each day. The process of scientific discovery is playing out in the public eye at a velocity not seen in recent memory. What could be viewed by the average consumer as confusing and hard to keep up with, is, by many in healthcare, viewed as innovation at its best. In the months since March 2020, the understanding of COVID-19 has evolved dramatically. We have watched a real-time shift in our understanding of how the virus is transmitted, who the most vulnerable populations are, and which treatments are most likely to work.
With so many patients being treated in acute care settings across the country, we—as a country—are better positioned than ever before to capitalize on de-identified, HIPAA-compliant patient data to inform scientists, researchers, and public health authorities with real-world evidence (RWE). As the number of infected patients and deaths continue to rise globally, clinicians around the world are struggling to fully understand all of the implications of the COVID-19 pandemic.
